Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting In May 2024
nab-Sirolimus demonstrated significantly greater intratumoral drug concentration, stronger inhibition of mTOR targets and greater antitumor activity compared to IV and…